Badania in vitro lekoodpornosci szczepow grzybow z rodzaju Candida

• Autorzy: Banach-Piatkowska W , Kotlowski A. , Humanowska J. , Mayer L. , Kowalczyk D.
• Języki publikacji: PL

Abstrakty

EN

The purpose of this study was to determine the in vitro susceptibility to 6 antifungal agents of 143 strains of Candida species isolated from 545 patients with suspicion of fungal infection. Test ATB Fungus (bioMerieux) was used. Among all Candida isolates 91.6% were susceptible to tested polyenes and 32.9% to all azoles. Less susceptible to polyenes isolates were noted in low percentage (0.7 to 4.2%) and to azoles more frequcntly (32.9 to 41.2%). Candida isolates resistant to antifungal agents tested were dependent from the kind of clinical samples and species of fungi. Monitoring of the susceptibility to antifungal agents by ATB commercial test seems to be uscful tool for therapeutic purposes.

Słowa kluczowe

PL

lekoopornosc; grzyby; szczepy chorobotworcze; Candida; leki przeciwgrzybicze; badania in vitro

• Wydawca: -
• Czasopismo: Wiadomości Parazytologiczne
• Rocznik: 2001
• Tom: 47
• Numer: 4
• Opis fizyczny: s.811-816,tab.,bibliogr.

Twórcy

autor

Banach-Piatkowska W

• Instytut Medycyny Morskiej i Topikalnej, ul.Powstania Styczniowego 9b, 81-519 Gdynia

autor

Kotlowski A.

autor

Humanowska J.

autor

Mayer L.

autor

Kowalczyk D.

Bibliografia

• ARIAS A., AREYALO M. P., ANDRElJ A., RODRIGUEZ C., SIERRA A. 1994. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents. Mycoses 37(7-8): 285-289.
• ASAI K., TSUHIMORI N., OKONOGI K., PERFECT J. R., GOTOH O., YOSHIDA Y. 1999. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob. Agents Chemother. 43: 1163-1169.
• BOSHMAN C. R., BODNAR U. R., TORNATORE M. A., OBIAS A. A., NOSKIN G. A., ENGLUND K., POSTELNICK M. A., SURIANO T., PETERSON L. L. 1998. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob. Agents Chemother. 42: 734-738.
• CANNON R. D., FISHER F. J., NIIMI K., NIIMI M., ARISAWA M. 1998. Drug pumping mechanisms in Candida albicans. Nippon. Ishinkin. Gakkai. Zasshi. 39: 73-78.
• COWEN L E., SANGLARD D., CALABRESE D., SIRJUSINGH C., ANDERS0N J.B., COHN LM. 2000. Evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 182: 1515-1522.
• DOMIN N. A. 1998. Highly virulent pathogens - a postantibiotic era? Br. J. Theatre Nurs. 8: 14-18.
• HOBAN D. J., ZHANEL G. G., KARLOWSKI J. A. 1999. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates of blood cultures of neutropenic patients. Antimicrob. Agents Chemother. 43: 1463- 1464.
• KLEPSER M. E., LEWIS R. E., PFALLER M. A. 1998. Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options. Ann. Pharmacother. 32: 1353-1361.
• MAHAYANI R., VAZQUEZ J. A., ZERVOS M. J. 1995. Nosocomial candidiasis: epidemiology and drug resistance. Infect. Agents Dis. 4 (4): 248-285.
• PAWLIK B. 1980. Ocena wrażliwości grzybów drożdżopodobnych na chemioterapeutyki metodą dyfuzyjną. Diagn. Lab. 16: 273-178.
• VANDEN BOSSCHE H., DROMER F., IMPROVISI I., CHIU M., REX J. H., SANGI.ARD D. 1998. Antifungal drug resistance in pathogenic fungi. Med. Mycol. Suppl. 1: 119-128.
• VERDUYN LUNEL F. M., MEIS J. F., VOSS A. 1999. Nosocomial fungal infections: candidemia. Diagn. Microbiol. Infect. Dis. 34: 213-220.